ArticleAging and disease2025
Exploring the Complex Relationship between Biological Aging and Cancer in a Prospective Italian Population Cohort.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Moderate Wine Consumption, Defined by the Mediterranean Diet, Is Associated With Delayed Biological Aging in Men From the Moli-sani Study.International journal of public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is often associated with age-related chronic conditions; however, the role of biological aging as a potential risk factor for cancer remains unclear and largely unexplored. To clarify this link, we tested the influence of two biological aging measures in an Italian prospective population cohort, the Moli-sani study (N=24,325; age ≥35 years; 51.9% women). For each participant these were based on the difference between first and a second-generation blood-based biological age estimates (BloodAge and PhenoAge) and chronological age. The resulting biological aging acceleration measures (BloodAgeAcc and PhenoAgeAcc) were tested for association with cancer mortality, first hospitalization and incident fatal/non-fatal cases, using multivariable Cox proportional hazard models. We analyzed 22,985 apparently cancer-free participants with mortality data available (median follow-up 13.1 years) and found independent increases in mortality rates per one-year increase in PhenoAgeAcc and BloodAgeAcc. Additionally, statistically significant increased risk of cancer hospitalizations was observed for PhenoAgeAcc. The analysis of incident cancers for different body sites identified both increased and decreased risks associated with biological aging acceleration. BloodAgeAcc was indeed weakly associated with a reduced risk of both breast and prostate cancer, but with an increased risk of pancreatic cancer, while PhenoAgeAcc was associated with an increased risk of lung and renal cancer. Our findings suggest that biological aging acceleration may differently impact cancer-related risks, with protective effects for some cancers versus increased risks for others. Further independent cohort studies are needed to clarify the translational clinical impact of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.